Arcturus Therapeutics, Inc.
Clinical trials sponsored by Arcturus Therapeutics, Inc., explained in plain language.
RNA medicines company developing mRNA-based therapies and vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New mRNA drug hopes to help cystic fibrosis patients who Can't use current therapies Results expected Jun 2027 (estimated)
-
New mRNA flu vaccine shows promise in early human trial
Vaccine CompletedThis early-stage trial tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza. 212 healthy adults aged 18-80 received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus placebo. Researchers monitor…
Phase 1/2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Vaccine
Last updated Sep 06, 2026 00:00 UTC
-
New combo vaccine study: COVID-19 and flu shot together in one visit
Vaccine CompletedThis study tested a new type of COVID-19 vaccine (ARCT-2303) in adults who had already received a COVID-19 vaccine. Some participants got the COVID-19 vaccine at the same time as the seasonal flu shot, while others got it alone. The goal was to see if the combination was safe and…
Phase 3 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:03 UTC
-
New Self-Amplifying RNA vaccines show promise in early COVID-19 trial
Vaccine CompletedThis study tested three new self-amplifying RNA vaccines against COVID-19 in 72 healthy adults, some already vaccinated and some not. The goal was to check safety and how well the vaccines boost the immune system. Results help decide which vaccine candidates to study further.
Phase 1/2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 07:54 UTC
-
New mRNA flu vaccine shows promise in first human trial
Vaccine CompletedThis early-stage trial tested a new type of flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially provide stronger and longer-lasting protection. The study involved 139 healthy adults aged 18-49 and 65-85, who received either the experimental vac…
Phase 1 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC